Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

FDA approves Santen's levofloxacin eyedrops

Aug. 22, 2000

New compounds interacting with glutathione reductase useful for cataracts, etc.

Aug. 21, 2000

QLT and Ciba Vision seek expanded labeling for Visudyne

Aug. 18, 2000

Bausch & Lomb and Muro to copromote Optivar

Aug. 16, 2000

Retinoid supplementation improves mouse model of childhood blindness

Aug. 11, 2000

FDA approves Rescula for treatment of glaucoma

Aug. 7, 2000

Visudyne approved in E.U. for treatment of wet AMD

Aug. 1, 2000

Tetracyclines as a valuable and relatively safe therapy for corneal ulceration

July 31, 2000

Topically applied GAG synthesis inhibitors useful for corneal haze

July 27, 2000

Nucleotides in development at Inspire for various clinical indications

July 20, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...